Cahan A C, Ashikari R, Pressman P, Cody H, Hoffman S, Sherman J E
Beth Israel Medical Center, North Division, New York, NY, USA.
Ann Surg Oncol. 1995 Mar;2(2):121-5. doi: 10.1007/BF02303626.
Although epidemiological studies have failed to demonstrate an increased incidence of breast cancer in women who had undergone prior prosthetic augmentation mammoplasty (PAM), it has been reported that when breast cancer arises in this group it presents mostly in a palpable form and at a more advanced stage. This is thought to be secondary to suboptimal mammographic evaluation caused by the masking effect of the implant. This study was undertaken to determine, in our experience, whether breast cancer arising in women who had undergone PAM could be detected in a prepalpable form by mammography and whether it presented at a more advanced stage as compared with nonaugmented women with breast cancer.
The charts of 22 patients, treated by at least one of the authors, in whom 23 breast cancers developed after PAM (group A) were retrospectively reviewed. The comparison groups consisted of 611 nonaugmented patients who underwent 636 procedures for the treatment of primary breast cancer at our institution (group B) and the surveillance, epidemiology, and end results (SEER) data (group C). Parameters studied were mode of detection, tumor size, axillary lymph node involvement, and histopathology.
No significant differences between the groups were found in mean tumor size (group A vs. group B), the incidence of preinvasive cancer (group A vs. group B) or axillary lymph node involvement (group A vs. group B and group A vs. group C). Breast-preserving surgery was performed significantly less in augmented patients (group A vs. group B).
We conclude that prepalpable and preinvasive breast cancer can be detected in the PAM patient by mammography and that the stage of presentation in this group is not significantly different than in nonaugmented patients. Total mastectomy is preferred over breast-preserving procedures for the treatment of breast cancer in the PAM patient.
尽管流行病学研究未能证明既往接受过假体隆乳术(PAM)的女性患乳腺癌的发病率增加,但有报道称,该组女性患乳腺癌时大多表现为可触及的形式且处于更晚期阶段。这被认为是由于植入物的掩盖效应导致乳腺钼靶评估欠佳所致。本研究旨在根据我们的经验,确定接受过PAM的女性所患乳腺癌是否能通过乳腺钼靶以不可触及的形式被检测到,以及与未行隆乳术的乳腺癌女性相比,其是否处于更晚期阶段。
回顾性分析至少一位作者治疗的22例患者的病历,这些患者在PAM后发生了23例乳腺癌(A组)。比较组包括611例未行隆乳术的患者,他们在我们机构接受了636例原发性乳腺癌治疗手术(B组)以及监测、流行病学和最终结果(SEER)数据(C组)。研究的参数包括检测方式、肿瘤大小、腋窝淋巴结受累情况和组织病理学。
在平均肿瘤大小(A组与B组)、原位癌发病率(A组与B组)或腋窝淋巴结受累情况(A组与B组以及A组与C组)方面,各组之间未发现显著差异。接受隆乳术的患者保乳手术的实施率显著低于未隆乳患者(A组与B组)。
我们得出结论,乳腺钼靶可在接受PAM的患者中检测到不可触及和原位乳腺癌,并且该组患者的发病阶段与未行隆乳术的患者相比无显著差异。对于接受PAM的患者,乳腺癌治疗首选全乳切除术而非保乳手术。